Liver-specific T regulatory type-1 cells program local neutrophils to suppress hepatic autoimmunity via CRAMP
Channakeshava Sokke Umeshappa,Patricia Solé,Bas G J Surewaard,Jun Yamanouchi,Saswat Mohapatra,Muhammad Myn Uddin,Robert Clarke,Mireia Ortega,Santiswarup Singha,Debajyoti Mondal,Yang Yang,Dario A A Vignali,Pau Serra,Paul Kubes,Pere Santamaria,Bas G.J. Surewaard,Dario A.A. Vignali
DOI: https://doi.org/10.1016/j.celrep.2021.108919
IF: 8.8
2021-03-01
Cell Reports
Abstract:Neutrophils with immunoregulatory properties, also referred to as type-2 neutrophils (N2), myeloid-derived suppressor cells (MDSCs), or tumor-associated neutrophils (TANs), comprise a heterogeneous subset of cells that arise from unknown precursors in response to poorly understood cues. Here, we find that, in several models of liver autoimmunity, pharmacologically induced, autoantigen-specific T regulatory type-1 (TR1) cells and TR1-cell-induced B regulatory (B<sub>reg</sub>) cells use five immunoregulatory cytokines to coordinately recruit neutrophils into the liver and program their transcriptome to generate regulatory neutrophils. The liver-associated neutrophils from the treated mice, unlike their circulating counterparts or the liver neutrophils of sick mice lacking antigen-specific TR1 cells, are proliferative, can transfer disease protection to immunocompromised hosts engrafted with pathogenic effectors, and blunt antigen-presentation and local autoimmune responses via cathelin-related anti-microbial peptide (CRAMP), a cathelicidin, in a CRAMP-receptor-dependent manner. These results, thus, identify antigen-specific regulatory T cells as drivers of tissue-restricted regulatory neutrophil formation and CRAMP as an effector of regulatory neutrophil-mediated immunoregulation.
cell biology